Posts in tag

substitution


Pharmacists now able to substitute alternatives for menopause treatment after a scarcity notification was issued    The Therapeutic Goods Administration (TGA) has advised of a shortage of all strengths of …

Community pharmacists are now able to substitute Actemra formulations without prior prescriber approval, due to serious shortages Two tocilizumab (Actemra) formulations are now effectively interchangeable at the pharmacy level after …

Pharmacy has a prominent role in the supply and provision of biosimilar medicines, and the profession has been slow to come to terms with this. Is the situation now changing? …

Mixed views over medicine substitution by pharmacists as Parliament debates TGA amendment bill There have been divergences of opinions expressed in Federal Parliament about the substitution of medicines by pharmacists …

Thousands of pharmacy and other retail jobs at risk from Jobseeker cuts as businesses and employees are set to suffer financially, MPs tell Parliament Federal parliamentarians have debated the impact …

Government releases details on proposed pharmacist medicine substitution process, but concerns are raised that it’s “too complex, too slow” The Therapeutic Goods Administration (TGA) has released details on the Federal …

During the COVID-19 pandemic, the general public badly needs certainty around access to medicines, says one pharmacy leader Following the postponement of the Pharmacy Guild’s flagship Australian Pharmacy Professional Conference …

Some pharmacists feel that they can make generic substitutions or changes to instructions where this is unauthorised, thinking these actions have no consequence – but that’s not the case In …

Pharmacists’ authority to use their expertise to substitute one medicine for another should also apply to biological medicines, says FIP The International Pharmaceutical Federation has published a revised Statement of …

The Consumers Health Forum has expressed its concerns about the issue of substitution of biological medicines with biosimilars, at a meeting called by the Pharmaceutical Benefits Advisory Committee. CEO of …